Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF in Toxic Epidermal Necrolysis
NCT02739295Phase 4Completed
- Sponsor
- University of Liège
- Start
- Jul 2016
- Primary completion
- Mar 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 4 trial of filgrastim in toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), sponsored by University of Liège. Started Jul 2016; status: completed.
02
Drugs
filgrastim
03
Conditions
toxic epidermal necrolysis (TEN)Stevens-Johnson syndrome (SJS)
Beyond the preview
Go deeper on NCT02739295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02739295.